Translational and Clinical Pharmacology

Korean Society for Clinical Pharmacology and Therapeutics (대한임상약리학회)
권호 표지
DOI QR코드

DOI QR Code

Development of a UPLC-MS/MS method for the therapeutic monitoring of L-asparaginase

  • Jeong, Hyeon-Cheol (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University) ;
  • Kim, Therasa (Department of Hematology, Chonnam National University Hwasun Hospital) ;
  • Yang, Deok-Hwan (Department of Hematology, Chonnam National University Hwasun Hospital) ;
  • Shin, Kwang-Hee (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
  • Received : 2018.06.06
  • Accepted : 2018.07.25
  • Published : 2018.09.15
⟨ Previous Next ⟩

Abstract

This study aimed to develop a UPLC-MS/MS method for determining plasma levels of L-aspartic acid and L-asparagine and the activity of L-asparaginase. L-aspartic acid, L-asparagine, and L-aspartic acid-2,3,3-$d_3$ were extracted from human plasma by protein precipitation with sulfosalicylic acid (30%, v/v). The plasma samples were analyzed using an Imtakt Intrada amino acid analysis column with 25 mM ammonium formate and 0.5% formic acid in acetonitrile as the mobile phase with step gradient method at a flow rate of 0.5 mL/min. The injection volume was $5{\mu}L$, and the total run time was 15 min. Inter- and intra-batch accuracies (%) ranged from 96.62-106.0% for L-aspartic acid and 89.85-104.8%, for L-asparagine, and the coefficient of variation (CV%) did not exceed 7%. The validation results for L-aspartic acid and L-asparagine satisfied the specified criterion, however, the results for L-asparaginase activity assay showed a borderline validity. This study could be a foundation for further development of therapeutic drug monitoring systems using UPLC-MS/MS.

Keywords

Acknowledgement

Supported by : National Research Foundation (NRF)

References

  1. Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma 2015;56:2273-2280. doi:10.3109/10428194.2014.1003056.
  2. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998;28:97-113. doi: Doi 10.1016/S1040-8428(98)00015-8.
  3. Kumar K, Kaur J, Walia S, Pathak T, Aggarwal D. L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia. Leuk Lymphoma 2014;55:256-262. doi: 10.3109/10428194.2013.803224.
  4. Boos J, Werber G, Ahlke E, Schulze-Westhoff P, Nowak-Gottl U, Wurthwein G, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550. doi:Doi 10.1016/0959-8049(96)00131-1.
  5. Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109:2744-2750. doi:10.1182/blood-2006-07-035006.
  6. Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, Hempel G, Muller HJ, Lumkemann K, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999;104:313-320. https://doi.org/10.1046/j.1365-2141.1999.01192.x
  7. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, Werber G, Borste H, Wurthwein G, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol 1997;96:675-681. doi: DOI 10.1046/j.1365-2141.1997.d01-2089.x.
  8. Rizzari C, Zucchetti M, Conter V, Diomede L, Bruno A, Gavazzi L, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E-coli L-asparaginase as first exposure. Ann Oncol 2000;11:189-193. doi: Doi 10.1023/A:1008368916800.
  9. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L-asparaginase treatment in acute lymphoblastic leukemia. Cancer 2011;117:238-249. doi: 10.1002/cncr.25489.
  10. Wetzler M, Sanford BL, Kurtzberg J, DeOliveira D, Frankel SR, Powell BL, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007;109:4164-4167. doi: 10.1182/blood-2006-09-045351.
  11. Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma 2015;56:2273-2280. doi:10.3109/10428194.2014.1003056.
  12. Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, Wetzler M. Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev 2015;29:243-249. doi: 10.1016/j.blre.2015.01.001.
  13. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999;13:335-342. https://doi.org/10.1038/sj.leu.2401310
  14. Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:7161-7167. doi: 10.1200/JCO.2005.11.411.
  15. Nath CE, Dallapozza L, Eslick AE, Misra A, Carr D, Earl JW. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia. Biomed Chromatogr 2009;23:152-159. doi:10.1002/bmc.1096.
  16. Lanvers C, Vieira Pinheiro JP, Hempel G, Wuerthwein G, Boos J. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002;309:117-126. https://doi.org/10.1016/S0003-2697(02)00232-4
  17. Kaspar H, Dettmer K, Gronwald W, Oefner PJ. Advances in amino acid analysis. Anal Bioanal Chem 2009;393:445-452. doi: 10.1007/s00216-008-2421-1.
  18. Thakare R, Chhonker YS, Gautam N, Alamoudi JA, Alnouti Y. Quantitative analysis of endogenous compounds. J Pharm Biomed Anal 2016;128:426-437. doi: 10.1016/j.jpba.2016.06.017.
  19. Jones BR, Schultz GA, Eckstein JA, Ackermann BL. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis 2012;4:2343-2356. doi: 10.4155/Bio.12.200.
  20. Shama N, Bai SW, Chung BC, Jung BH. Quantitative analysis of 17 amino acids in the connective tissue of patients with pelvic organ prolapse using capillary electrophoresis-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;865:18-24. doi: 10.1016/j.jchromb.2008.01.027.
  21. MFDS. Guideline on Bioanalytical Method Validation. http://nifds.go.kr/_custom/nifds/_common/board/download.jsp?attach_no=18470/ Accessed 6 September 2017
  22. Tong WH, Pieters R, Kaspers GJ, te Loo DM, Bierings MB, van den Bos C, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014;123:2026-2033. doi: 10.1182/blood-2013-10-534347.
  23. Schrey D, Borghorst S, Lanvers-Kaminsky C, Hempel G, Gerss J, Moricke A, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr Blood Cancer 2010;54:952-958. doi:10.1002/pbc.22417.
  24. Lanvers C, Vieira Pinheiro JP, Hempel G, Wuerthwein G, Boos J.. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem 2002;309:117-126. doi: Pii S0003-2697(02)00232-4 https://doi.org/10.1016/S0003-2697(02)00232-4
  25. Appel IM, Kazemier KM, Boos J, Lanvers C, Huijmans J, Veerman AJ, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEGasparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia 2008;22:1665-1679. doi: 10.1038/leu.2008.165.